| Component: (Network and Table) | |
|---|---|
| Network | 105 - Statement - Consolidated Statements of Operations (http://www.abiomed.com/taxonomy/role/StatementOfIncomeAlternative) |
| Table | Statement [Table] |
| Reporting Entity [Axis] | 0000815094 (http://www.sec.gov/CIK) |
| Legal Entity [Axis] | Entity [Domain] |
| Statement [Line Items] | Period [Axis] | ||
|---|---|---|---|
2011-04-01 - 2012-03-31 | 2010-04-01 - 2011-03-31 | 2009-04-01 - 2010-03-31 | |
Revenue: | |||
Product revenue | 125,286,000 | 99,837,000 | 84,765,000 |
Funded research and development | 1,089,000 | 1,314,000 | 948,000 |
Revenues, Total | 126,375,000 | 101,151,000 | 85,713,000 |
Costs and expenses: | |||
Cost of product revenue | 24,507,000 | 21,977,000 | 22,529,000 |
Research and development | 27,159,000 | 26,677,000 | 25,954,000 |
Selling, general and administrative | 71,711,000 | 62,287,000 | 60,837,000 |
Amortization of intangible assets | 1,478,000 | 1,395,000 | 1,469,000 |
Costs and Expenses, Total | 124,855,000 | 112,336,000 | 110,789,000 |
Income (loss) from operations | 1,520,000 | (11,185,000) | (25,076,000) |
Other income (expense): | |||
Investment (expense) income, net | (3,000) | 9,000 | 373,000 |
Gain on sale of WorldHeart stock | 456,000 | 6,389,000 | |
Gain on settlement of investment | 1,017,000 | ||
Other income (expense), net | 9,000 | (143,000) | (39,000) |
Nonoperating Income (Expense), Total | 1,023,000 | 322,000 | 6,723,000 |
Income (loss) before income tax provision | 2,543,000 | (10,863,000) | (18,353,000) |
Income tax provision | 1,048,000 | 892,000 | 671,000 |
Net income (loss) | 1,495,000 | (11,755,000) | (19,024,000) |
Basic net income (loss) per share | .04 | (.32) | (.52) |
Basic weighted average shares outstanding | 38,374,000 | 37,167,000 | 36,875,000 |
Diluted net income (loss) per share | .04 | (.32) | (.52) |
Diluted weighted average shares outstanding | 40,172,000 | 37,167,000 | 36,875,000 |